Commercialization

Sibeprenlimab Receives U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy

Retrieved on: 
Friday, February 16, 2024

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease).
  • This press release features multimedia.
  • Breakthrough therapy designation allows the agency to prioritize and focus resources on the most promising products for which no satisfactory treatment option exists.
  • “We are encouraged by the FDA’s decision to grant breakthrough therapy status for the sibeprenlimab program,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer at Otsuka.

Northeastern University and Open 6G OTIC Partners with AT&T and Verizon to Advance Open and Interoperable Cellular Networks in NTIA T&E Award

Retrieved on: 
Wednesday, February 14, 2024

"We are happy to work with leading operators and vendors to advance the Open RAN ecosystem," says Tommaso Melodia, Director of WIoT at Northeastern University.

Key Points: 
  • "We are happy to work with leading operators and vendors to advance the Open RAN ecosystem," says Tommaso Melodia, Director of WIoT at Northeastern University.
  • The Northeastern University Open 6G OTIC is a one-stop shop for Open RAN innovation.
  • It serves as a hub for the development and testing of next-generation wireless networks utilizing Open RAN technology and Artificial Intelligence.
  • The Northeastern University OTIC can also test massive Multiple Input, Multiple Output (MIMO) radios, key to improving the spectral efficiency of Open RAN.

DOCOMO to Collaborate with AT&T, Verizon and Jio for Open RAN Verifications

Retrieved on: 
Tuesday, February 13, 2024

TOKYO, Feb 13, 2024 - (JCN Newswire) - NTT DOCOMO, INC. announced today that it will participate in Open RAN verifications in the United States as the ACCoRD (Acceleration of Compatibility and Commercialization for Open RAN Deployments) project in a consortium jointly founded with AT&T Inc. (AT&T), Verizon Communications Inc. (Verizon), and Reliance Jio Infocomm Ltd. (Jio).

Key Points: 
  • TOKYO, Feb 13, 2024 - (JCN Newswire) - NTT DOCOMO, INC. announced today that it will participate in Open RAN verifications in the United States as the ACCoRD (Acceleration of Compatibility and Commercialization for Open RAN Deployments) project in a consortium jointly founded with AT&T Inc. (AT&T), Verizon Communications Inc. (Verizon), and Reliance Jio Infocomm Ltd. (Jio).
  • This consortium was awarded a USD 42.3 million grant from the U.S. Department of Commerce National Telecommunications and Information Administration (NTIA)(1) on February 12.
  • The consortium comprises telecom operators and US universities and suppliers include equipment vendors from the United States and abroad, and is committed to verifying multi-vendor Open RAN connectivity for further commercial deployments.
  • (2) OREX is an Open RAN service provider launched by DOCOMO in collaboration with multiple global vendors, providing customized Open RAN solutions to address the needs of each customer.

Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease

Retrieved on: 
Monday, February 12, 2024

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).

Key Points: 
  • Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and our parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) announce topline results of the phase 3 clinical trial of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease (Trial 17-AVP-786-305; NCT03393520).
  • There were 4 deaths reported in the trial; 1 (0.5%) in the AVP-786 low dose group and 3 (1.4%) in the placebo group.
  • Further prespecified and exploratory analyses of the data set will be conducted to determine the full potential of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease.
  • “While the result of this trial is disappointing, we plan to analyze the full data set to determine the future potential of AVP-786 in the treatment of agitation associated with dementia due to Alzheimer’s disease.

Lauren Barnes Joins Ossium Health’s Board of Directors

Retrieved on: 
Monday, February 12, 2024

Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors.

Key Points: 
  • Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors.
  • “Lauren’s expertise and proven track record in biopharmaceutical commercialization are invaluable assets,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President.
  • In addition, Barnes serves as a board member for Ascelia Pharma AB, a Swedish oncology drug development company with two late-stage drug candidates, and she recently completed her time as Chair of the Board of Directors for the non-profit Cancer Support Community.
  • “I am incredibly excited to join Ossium’s Board of Directors at this pivotal moment in the company’s journey,” said Barnes.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Aprecia Names Andrew Karazim as New Chief Commercial Officer

Retrieved on: 
Wednesday, February 7, 2024

BLUE ASH, Ohio, Feb. 7, 2024 /PRNewswire/ -- Aprecia, the global leader in 3DP technology for commercial-scale pharmaceutical manufacturing, today announced Andrew Karazim will lead Aprecia's Commercialization efforts as the Chief Commercial Officer. Karazim has more than 25 years of pharmaceutical and biotechnology experience with expertise across sales, marketing and market access.

Key Points: 
  • BLUE ASH, Ohio, Feb. 7, 2024 /PRNewswire/ -- Aprecia, the global leader in 3DP technology for commercial-scale pharmaceutical manufacturing, today announced Andrew Karazim will lead Aprecia's Commercialization efforts as the Chief Commercial Officer.
  • Karazim has more than 25 years of pharmaceutical and biotechnology experience with expertise across sales, marketing and market access.
  • "Mr. Karazim is an accomplished executive with a breadth of expertise focused on commercialization efforts and business strategies to drive growth.
  • Karazim spent the first 22 years of his career at Lilly in a variety of Commercial leadership positions in the US and Globally.

Rehabtronics Selected by Praxis Spinal Cord Institute to Launch Prelivia Pilot Program with Providence Health Care Ventures, Pioneering Innovative Solutions to Combat Pressure Injuries

Retrieved on: 
Tuesday, February 6, 2024

Pressure injuries are a common medical complication of paralysis and immobility, and people living with Spinal Cord Injuries (SCI) are at an elevated risk of developing them.

Key Points: 
  • Pressure injuries are a common medical complication of paralysis and immobility, and people living with Spinal Cord Injuries (SCI) are at an elevated risk of developing them.
  • Praxis Spinal Cord Institute, a global leader in spinal cord injury research and innovation, has recognized the expertise and commitment of Rehabtronics in advancing technology related to pressure injuries for people with SCI.
  • "We are thrilled to be selected by the Praxis Spinal Cord Institute for this important initiative," said Rahul Samant, CEO at Rehabtronics.
  • We look forward to working with the Praxis Spinal Cord Institute and Providence Health Care Ventures in accomplishing our shared vision of transforming pressure injury care."

Coherent Selected for Funding by the Department of Energy for Its Li-S Battery Technology for Next-Generation Electric Vehicles

Retrieved on: 
Wednesday, January 31, 2024

PITTSBURGH, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in engineered materials, has been selected for multimillion-dollar funding under the Department of Energy (DOE) Fiscal Year 2023 Vehicle Technologies Office (VTO) Program Wide Funding Opportunity Announcement (FOA-0002893).

Key Points: 
  • PITTSBURGH, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in engineered materials, has been selected for multimillion-dollar funding under the Department of Energy (DOE) Fiscal Year 2023 Vehicle Technologies Office (VTO) Program Wide Funding Opportunity Announcement (FOA-0002893).
  • This funding will accelerate the development of Coherent’s patented chemical immobilization technology for lithium sulfur (Li-S) battery cells to meet next-generation electric vehicle (EV) requirements.
  • Coherent will build demonstration cells that target energy densities exceeding today’s best-in-class EV batteries while retaining more than 80% of their original capacity after 1,000 recharging cycles.
  • As such, sulfur cathodes have the potential to both secure supply chains and support the strong and growing EV market.

Plastics Hall of Fame Announces Class of 2024 Inductees

Retrieved on: 
Thursday, February 1, 2024

MINNEAPOLIS, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Seventeen new members will be honored at the Class of 2024 induction ceremony on Sunday, May 5, 2024, in the Orange County Convention Center, Orlando, FL.

Key Points: 
  • Seventeen new Plastic Hall of Fame members will be honored at the Class of 2024 induction ceremony on Sunday, May 5, 2024, in the Orange County Convention Center, Orlando, FL.
  • MINNEAPOLIS, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Seventeen new members will be honored at the Class of 2024 induction ceremony on Sunday, May 5, 2024, in the Orange County Convention Center, Orlando, FL.
  • Established in 1972, the Plastics Hall of Fame has grown to 236 members representing nine countries, which include five Nobel Prize winners in chemistry.
  • The Plastics Hall of Fame recognizes the outstanding achievements of such individuals and inspires those entering the industry around the world.